Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.Contemporary clinical trials · 2017Trial
- Trial
- Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and prevention.Antimicrobial agents and chemotherapy · 2026Review
- Predictors of HIV Among 1 Million Clients in High-Risk Male Populations in Tanzania.AIDS and behavior · 2022Article
- Tissue-specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART-treated women.Journal of the International AIDS Society · 2021Article
- Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy.The Journal of infectious diseases · 2021Article
- Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma.AIDS (London, England) · 2020Article
- HIV-1 heterosexual transmission and association with sexually transmitted infections in the era of treatment as prevention.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2019Article
- Antiretroviral adherence and virologic suppression in partnered and unpartnered HIV-positive individuals in southern Brazil.PloS one · 2019Article
- HIV and SIV in Body Fluids: From Breast Milk to the Genitourinary Tract.Current immunology reviews · 2019Article
- Does B Cell Follicle Exclusion of CD8+ T Cells Make Lymph Nodes Sanctuaries of HIV Replication?Frontiers in immunology · 2019Review
- High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy.The Journal of antimicrobial chemotherapy · 2018Article
- Peering into the HIV reservoir.Reviews in medical virology · 2018Review
- Tissue reservoirs of HIV.Current opinion in HIV and AIDS · 2016Review
- HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?Journal of virus eradication · 2015Article
- Sex-based differences in HIV type 1 pathogenesis.The Journal of infectious diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 5 countries.
Funding
Abstract
backgroundCombination antiretroviral therapy (cART) reduces genital tract human immunodeficiency virus type 1 (HIV-1) load and reduces the risk of sexual transmission, but little is known about the efficacy of cART for decreasing genital tract viral load (GTVL) and differences in sex or HIV-1 subtype.
methodsHIV-1 RNA from blood plasma, seminal plasma, or cervical wicks was quantified at baseline and at weeks 48 and 96 after entry in a randomized clinical trial of 3 cART regimens.
resultsOne hundred fifty-eight men and 170 women from 7 countries were studied (men: 55% subtype B and 45% subtype C; women: 24% subtype B and 76% subtype C). Despite similar baseline CD4(+) cell counts and blood plasma viral loads, women with subtype C had the highest GTVL (median, 5.1 log10 copies/mL) compared to women with subtype B and men with subtype C or B (4.0, 4.0, and 3.8 log10 copies/mL, respectively; P < .001). The proportion of participants with a GTVL below the lower limit of quantification (LLQ) at week 48 (90%) and week 96 (90%) was increased compared to baseline (16%; P < .001 at both times). Women were significantly less likely to have GTVL below the LLQ compared to men (84% vs 94% at week 48, P = .006; 84% vs 97% at week 96, P = .002), despite a more sensitive assay for seminal plasma than for cervical wicks. No difference in GTVL response across the 3 cART regimens was detected.
conclusionsThe female genital tract may serve as a reservoir of persistent HIV-1 replication during cART and affect the use of cART to prevent sexual and perinatal transmission of HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.